Reuters -- H. Lundbeck A/S (Lundbeck) today announced that it has signed an agreement with Kyowa
Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) providing Lundbeck with exclusive rights to
develop and commercialise the adenosine A2a antagonist KW-6356. Lundbeck will also have
the right to further select compounds as either back-up or additional indication
compounds. Adenosine A2a antagonists have potential applications in a wide range of
therapeutic indications, including Parkinson's disease. Kyowa Hakko Kirin will retain
rights to develop and commercialise the compounds in Japan and the Asian region.
